Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals3.39%-1.02 ppManaged Health Care0.87%-0.85 ppLife Sciences Tools & Services0.91%-0.49 ppBiotechnology1.80%-0.32 ppHealth Care Equipment2.26%-0.27 ppHealth Care Services0.45%-0.07 ppHealth Care Distributors0.40%+0.07 ppHealth Care Supplies0.08%-0.06 ppHealth Care Facilities0.20%-0.04 ppHealth Care Technology0.03%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.80%
Industry change · 12M
-0.32 pp
Biotechnology · contribution
-0.323 pp
Company participation
38%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Sep 2025 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals → REGN | United States | $52.8bn | 0.106% | -0.001 pp | -0.124 pp | -46.3% | No |
| Amgen → AMGN | United States | $151.9bn | 0.304% | -0.020 pp | -0.099 pp | -9.5% | No |
| Vertex Pharmaceuticals → VRTX | United States | $100.4bn | 0.201% | -0.046 pp | -0.078 pp | -15.8% | No |
| Moderna → MRNA | United States | $10.0bn | 0.020% | -0.003 pp | -0.040 pp | -61.3% | No |
| Gilead Sciences → GILD | United States | $137.7bn | 0.276% | -0.022 pp | +0.033 pp | +36.3% | No |
| Biogen → BIIB | United States | $20.5bn | 0.041% | +0.001 pp | -0.025 pp | -27.7% | Yes |
| AbbVie → ABBV | United States | $409.0bn | 0.819% | +0.112 pp | +0.007 pp | +21.4% | Yes |
| Incyte → INCY | United States | $16.6bn | 0.033% | +0.005 pp | +0.004 pp | +28.3% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.